Fred Alger Management’s ACELYRIN SLRN Stock Holding History

Fred Alger Management’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-53,206	Closed	-$541K	–	491
2023 Q3	$541K	Sell	53,206 -956,843	-95%	-$20.3M	﹤0.01%	376
2023 Q2	$21.1M	Buy	+1,010,049	New	+$20.7M	0.11%	155

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fred Alger Management's SLRN Position: Q4 2023 in Review

Fred Alger Management sold out of ACELYRIN (SLRN) in Q4 2023, closing a stake of 53,206 shares — an estimated $541K sold.

Fred Alger Management first reported a position in SLRN in Q2 2023 and held it in 2 quarters. The position peaked at $21.1M in Q2 2023. 110 funds tracked by Wall St. Rank hold SLRN as of Q4 2023.

Fred Alger Management reported no remaining ACELYRIN position as of Q4 2023 after selling out during the quarter.
Fred Alger Management sold 53,206 ACELYRIN shares in Q4 2023, an estimated $541K.
Fred Alger Management first reported a position in ACELYRIN in Q2 2023 and held it in 2 quarters.
Fred Alger Management's ACELYRIN position peaked at $21.1M in Q2 2023.
110 funds tracked by Wall St. Rank held ACELYRIN as of Q4 2023.

Based on Fred Alger Management's 13F filing for Q4 2023, filed 14 Feb 2024.